Dengue Hemorrhagic Fever, a subset of the disease that can occur after reinfection with another strain of the same virus, has a case fatality rate of up to 20%.


Before the opening bell on Monday, NNVC reported that the European Medicines Agency (EMA), has awarded orphan drug-designation to DengueCide(TM), its drug-candidate for the treatment of dengue and dengue hemorrhagic fever.


This orphan drug-designation enables several benefits for NNVC’s dengue drug-development program. These benefits include “protocol assistance,” or specific scientific advice that can speed up the drug-development program, as well as certain fee reductions, for drug-approval(s) under EMA.